Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015 - a retrospective observational study
2019
Kerber, Romy | Lorenz, Eva | Duraffour, Sophie | Sissoko, Daouda | Rudolf, Martin | Jaeger, Anna | Cisse, Sekou Ditinn | Camara, Alseny-Modet | Miranda, Osvaldo | Castro, Carlos M | Akoi Bore, Joseph | Raymond Koundouno, Fara | Repits, Johanna | Afrough, Babak | Becker-Ziaja, Beate | Hinzmann, Julia | Mertens, Marc | Vitoriano, Ines | Hugh Logue, Christopher | Böttcher, Jan-Peter | Pallasch, Elisa | Sachse, Andreas | Bah, Amadou | Cabeza-Cabrerizo, Mar | Nitzsche, Katja | Kuisma, Eeva | Michel, Janine | Holm, Tobias | Gayle Zekeng, Elsa | Cowley, Lauren A | Garcia-Dorival, Isabel | Hetzelt, Nicole | Josef Baum, Jonathan Hans | Portmann, Jasmine | Carter, Lisa | Yenamaberhan, Rahel Lemma | Camino, Alvaro | Enkirch, Theresa | Singethan, Katrin | Meisel, Sarah | Mazzarelli, Antonio | Kosgei, Abigail | Kafetzopoulou, Liana | Rickett, Natasha Y | Patrono, Livia Victoria | Ghebreghiorghis, Luam | Arnold, Ulrike | Colin, Géraldine | Juchet, Sylvain | Marchal, Claire Levy | Kolie, Jacques Seraphin | Beavogui, Abdoul Habib | Wurr, Stephanie | Bockholt, Sabrina | Krumkamp, Ralf | May, Jürgen | Stoecker, Kilian | Fleischmann, Erna | Ippolito, Giuseppe | W Carroll, Miles | Koivogui, Lamine | Magassouba, N'Faly | Keita, Sakoba | Gurry, Céline | Drury, Patrick | Diallo, Boubacar | Formenty, Pierre | Wölfel, Roman | Caro, Antonino Di | Gabriel, Martin | Anglaret, Xavier | Malvy, Denis | Günther, Stephan
BACKGROUND:In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. Cycle threshold (Ct) in the Ebola virus RT-PCR and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to EVD patients on compassionate use basis. METHODS:To reduce biases in the raw field data, we carefully selected 163 of the 286 EVD patients for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry, favipiravir treatment, and outcome. RESULTS:The case fatality rate in favipiravir-treated patients was lower than in untreated patients (31/73 [42.5%] vs. 52/90 [57.8%], p = 0.053 in univariate analysis). In the multivariate regression analysis, higher Ct value and younger age were associated with survival (p <0.001), while favipiravir treatment showed no statistically significant effect (p = 0.11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (p = 0.015). The study also showed characteristic changes in blood chemistry in fatal cases vs. survivors. CONCLUSIONS:Consistent with the JIKI trial, this retrospective study reveals a trend toward improved survival in favipiravir-treated patients; however, the effect was not statistically significant except for survival time.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
Publisher Oxford Univ. Press
ISSN 1537-6613 | 0022-1899This bibliographic record has been provided by Friedrich-Loeffler-Institut
